Unlike a large number of in vitro and in vivo studies that have evaluated the therapeutic efficacy of targeting IL-33/ST2 signal in colorectal, gastric, ovarian cancers, and melanoma,7,8 the evaluation of the therapeutic efficacy of targeting IL-33/ST2 signal in esophageal cancer (both ESCC and ECA) is still limited and needs more exploration, both in vivo and in vitro. Here, IL33 is linked to ovarian cancer.